{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=17",
    "query": {
      "intervention": "Placebo IV infusion",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1859,
    "total_pages": 186,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T19:23:02.732Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05938036",
      "title": "Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "ALT-100 mAb",
          "type": "DRUG"
        },
        {
          "name": "ALT-100 (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aqualung Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-12-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938036"
    },
    {
      "nct_id": "NCT05139316",
      "title": "A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glycogen Storage Disease Type IA"
      ],
      "interventions": [
        {
          "name": "DTX401",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Oral prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for oral prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-11-08",
      "completion_date": "2026-02-20",
      "has_results": true,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 9,
      "location_summary": "Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139316"
    },
    {
      "nct_id": "NCT01629667",
      "title": "A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Tralokinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "50 Years to 79 Years"
      },
      "enrollment_count": 409,
      "start_date": "2012-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Sacramento, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01629667"
    },
    {
      "nct_id": "NCT04646044",
      "title": "A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid-19",
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-13",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 4,
      "location_summary": "Hialeah, Florida • Winter Park, Florida • Mesquite, Texas",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Mesquite",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04646044"
    },
    {
      "nct_id": "NCT04475198",
      "title": "Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute, Post-operative Pain"
      ],
      "interventions": [
        {
          "name": "ST-2427",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SiteOne Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-03-04",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04475198"
    },
    {
      "nct_id": "NCT03272165",
      "title": "Single Ascending Dose Study of MEDI1341 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "MEDI1341",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-10-17",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272165"
    },
    {
      "nct_id": "NCT01794663",
      "title": "Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "OPN-305",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opsona Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2012-10",
      "completion_date": "2016-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-02-16",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01794663"
    },
    {
      "nct_id": "NCT00158600",
      "title": "A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pompe Disease (Late-onset)",
        "Glycogen Storage Disease Type II (GSD-II)",
        "Acid Maltase Deficiency Disease",
        "Glycogenosis 2"
      ],
      "interventions": [
        {
          "name": "alglucosidase alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2005-09",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-28",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00158600"
    },
    {
      "nct_id": "NCT04634253",
      "title": "A Study of LY3462817 in Participants With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY3462817",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2021-01-04",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-12",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 7,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Palm Desert, California + 4 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634253"
    },
    {
      "nct_id": "NCT04412772",
      "title": "Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Queen's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-12",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-15T19:23:02.732Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04412772"
    }
  ]
}